{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:47:47Z","timestamp":1792154867478,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 placed strain on healthcare systems globally, including South Africa. While vaccine effectiveness is well established, context-specific evidence on the economic value of COVID-19 vaccination in African and real-world settings remains limited. This study evaluates the cost-effectiveness and cost-utility of COVID-19 vaccination within a South African population with private health insurance between 1 March 2020 and 30 December 2022 using claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A state-transition Markov model was developed in TreeAge Pro 2025 from a third-party payer perspective, comparing non-vaccination, partial vaccination, and full vaccination. Disease progression was simulated over a 60-year lifetime horizon using two-week cycles to capture acute and long-term health outcomes. Model inputs, including COVID-19-related hospitalisations, mortality, healthcare utilisation, and costs, were derived from insurance claims data for 550,332 individuals enrolled in two private health insurance funds during the study period. Outcomes included hospitalisations and deaths averted, life years (LYs) gained, and quality-adjusted life years (QALYs) gained. Costs and outcomes were discounted at 0% and 3% annually. Incremental cost-effectiveness and cost-utility ratios were calculated, and parameter uncertainty was assessed using one-way and probabilistic sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both partial and full vaccination strategies were associated with fewer base case hospitalisations and deaths, minor gains in life years and QALYs, and lower lifetime discounted costs per individual at base, with $49.32 for non-vaccination, $23.32 for partial vaccination, and $49.08 for full vaccination. Partial vaccination was dominant compared to non-vaccination, while full vaccination was cost-saving at base case and in most simulations. Compared to partial vaccination, full vaccination provided little QALY gains at an incremental cost of $25.72 per individual, resulting in an ICUR of $64,424 per QALY gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using real-world insurance claims data, COVID-19 vaccination was associated with improved long-term health outcomes within a South African privately insured population, with partial vaccination being cost-saving. The second dose provided limited additional value in this lower-risk cohort. These findings indicate that funding vaccination during the pandemic represented an efficient allocation of healthcare resources within the insured sector. Caution is warranted in generalising these results beyond populations with different demographic and risk profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-15121-w","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:54:28Z","timestamp":1784570068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness and cost-utility of COVID-19 vaccination in a South African privately insured population: a real-world claims-based analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-3119","authenticated-orcid":false,"given":"Geetesh","family":"Solanki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-9928","authenticated-orcid":false,"given":"Francesca","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-7958","authenticated-orcid":false,"given":"Susan","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"15121_CR1","unstructured":"Statement on the second meeting of the International Health Regulations. (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [press release]. Geneva WHO2020."},{"key":"15121_CR2","unstructured":"WHO Director-. General\u2019s opening remarks at the media briefing on COVID-19\u201311 March 2020 [press release]. Geneva WHO2020."},{"key":"15121_CR3","unstructured":"National Institute for Communicable Diseases. First case of COVID-19 Coronovirus reported in South Africa. 5. March 2020. https:\/\/www.nicd.ac.za\/first-case-of-covid-19-coronavirus-reported-in-sa\/"},{"key":"15121_CR4","unstructured":"National Institute for Communicable Diseases. Daily Hospital Surveilance (Datcov) Reports. https:\/\/www.nicd.ac.za\/diseases-a-z-index\/disease-index-covid-19\/surveillance-reports\/daily-hospital-surveillance-datcov-report\/"},{"issue":"8","key":"15121_CR5","first-page":"1354","volume":"11","author":"I Edoka","year":"2022","unstructured":"Edoka I, Fraser H, Jamieson L, Meyer-Rath G, Mdewa W. Inpatient Care Costs of COVID-19 in South Africa\u2019s Public Healthcare System. Int J Health Policy Manag. 2022;11(8):1354\u201361.","journal-title":"Int J Health Policy Manag"},{"key":"15121_CR6","doi-asserted-by":"crossref","unstructured":"Forsythe S, Cohen J, Neumann P, Bertozzi SM, Kinghorn A. The Economic and public health imperatives around making potential coronavirus disease\u20132019 Treatments available and affordable. value in health. 2020;23(11):1427-31.","DOI":"10.1016\/j.jval.2020.04.1824"},{"key":"15121_CR7","doi-asserted-by":"crossref","unstructured":"Oh I-H, Ock M, Jang SY, Go D-S, Kim Y-E, Jung Y-S et al. Years of life lost attributable to COVID-19 in high-incidence countries. J Korean Med Sci. 2020;35(32).","DOI":"10.3346\/jkms.2020.35.e300"},{"key":"15121_CR8","unstructured":"Nsomba G, Tshabalala, Vilakazi T. Analysis of the impact of COVID-19 on micro, small and medium sized enterprises in South Africa. Centre for Competition, Regulation and economic development (CCRED), University of johannesburg. 10 May 2021. https:\/\/www.compcom.co.za\/wp-content\/uploads\/2021\/11\/SMEs-COVID-19-in-South-Africa_Final-Report_CCRED-20210510-003.pdf"},{"issue":"5","key":"15121_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"T Thanh Le","year":"2020","unstructured":"Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"15121_CR10","doi-asserted-by":"crossref","unstructured":"Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19 Vaccine roll-out in south africa and zimbabwe: urgent need to address community preparedness, Fears and Hesitancy. Vaccines. 2021;9(3).","DOI":"10.3390\/vaccines9030250"},{"key":"15121_CR11","unstructured":"World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/table"},{"key":"15121_CR12","first-page":"252","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect diseases: IJID : official publication Int Soc Infect Dis. 2022;114:252\u201360.","journal-title":"Int J Infect diseases: IJID : official publication Int Soc Infect Dis"},{"issue":"1","key":"15121_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","volume":"10","author":"Q Liu","year":"2021","unstructured":"Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis poverty. 2021;10(1):132.","journal-title":"Infect Dis poverty"},{"issue":"1","key":"15121_CR14","doi-asserted-by":"publisher","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","volume":"18","author":"I Mohammed","year":"2022","unstructured":"Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"15121_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cmi.2022.01.033","volume":"28","author":"R Whittaker","year":"2022","unstructured":"Whittaker R, Br\u00e5then Kristofferson A, Valcarcel Salamanca B, Sepp\u00e4l\u00e4 E, Golestani K, Kv\u00e5le R, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis. 2022;28(6):871\u20138.","journal-title":"Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis"},{"key":"15121_CR16","doi-asserted-by":"publisher","first-page":"102632","DOI":"10.1016\/j.pmedr.2024.102632","volume":"39","author":"X Fang","year":"2024","unstructured":"Fang X, Tao G, Zhou H, Zhou Y. Vaccines reduced hospital length of stay and fraction of inspired oxygen of COVID-19 patients: A retrospective cohort study. Prev Med Rep. 2024;39:102632.","journal-title":"Prev Med Rep"},{"key":"15121_CR17","doi-asserted-by":"crossref","unstructured":"Somani ST, Firestone RL, Donnelley MA, Sanchez L, Hatfield C, Fine J et al. Impact of vaccination on cost and course of hospitalization associated with COVID-19 Infection. Antimicrobial stewardship & healthcare epidemiology: ASHE. 2023;3(1):e19.","DOI":"10.1017\/ash.2022.364"},{"issue":"14","key":"15121_CR18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMc2210093","volume":"387","author":"S Collie","year":"2022","unstructured":"Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. N Engl J Med. 2022;387(14):1332\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"15121_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2022;386(5):494\u20136.","journal-title":"N Engl J Med"},{"issue":"10330","key":"15121_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","volume":"399","author":"LG Bekker","year":"2022","unstructured":"Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399(10330):1141\u201353.","journal-title":"Lancet"},{"issue":"23","key":"15121_CR21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMc2202061","volume":"386","author":"G Gray","year":"2022","unstructured":"Gray G, Collie S, Goga A, Garrett N, Champion J, Seocharan I, et al. Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. N Engl J Med. 2022;386(23):2243\u20135.","journal-title":"N Engl J Med"},{"issue":"6","key":"15121_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/vaccines12060628","volume":"12","author":"R Kassanjee","year":"2024","unstructured":"Kassanjee R, Davies M-A, Heekes A, Mahomed H, Hawkridge AJ, Morden E, et al. COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020\u20132022. Vaccines. 2024;12(6):628.","journal-title":"Vaccines"},{"issue":"1","key":"15121_CR23","doi-asserted-by":"publisher","first-page":"e0317686","DOI":"10.1371\/journal.pone.0317686","volume":"20","author":"G Solanki","year":"2025","unstructured":"Solanki G, Cleary S, Little F. Impact of COVID-19 vaccination on hospitalization, hospital utilization and expenditure for COVID-19: A retrospective cohort analysis of a South African private health insured population. PLoS ONE. 2025;20(1):e0317686.","journal-title":"PLoS ONE"},{"issue":"1","key":"15121_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41256-022-00255-1","volume":"7","author":"BBB Ackah","year":"2022","unstructured":"Ackah BBB, Woo M, Stallwood L, Fazal ZA, Okpani A, Ukah UV, et al. COVID-19 vaccine hesitancy in Africa: a scoping review. Global Health Res Policy. 2022;7(1):21.","journal-title":"Global Health Res Policy"},{"issue":"1","key":"15121_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1744133112000060","volume":"8","author":"JE-O Ataguba","year":"2013","unstructured":"Ataguba JE-O, McIntyre D. Who benefits from health services in South Africa? Health Econ Policy Law. 2013;8(1):21\u201346.","journal-title":"Health Econ Policy Law"},{"issue":"1","key":"15121_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2022;25(1):3\u20139.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"5","key":"15121_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/heapol\/czz152","volume":"35","author":"IP Edoka","year":"2020","unstructured":"Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plann. 2020;35(5):546\u201355.","journal-title":"Health Policy Plann"},{"key":"15121_CR28","unstructured":"Stats SA. PO141- Consumer Price Index (CPI). CPI History. 11 June 2024. https:\/\/www.statssa.gov.za\/publications\/P0141\/CPIHistory.pdf?SCH=73795."},{"key":"15121_CR29","unstructured":"World Health Organisation. Regional Health Observatory. Life tables: Life tables by country: SOuth AFrica. June 2020. https:\/\/apps.who.int\/gho\/data\/view.searo.61540?lang=en"},{"key":"15121_CR30","doi-asserted-by":"publisher","first-page":"06001","DOI":"10.7189\/jogh.13.06001","volume":"13","author":"AM Utami","year":"2023","unstructured":"Utami AM, Rendrayani F, Khoiry QA, Noviyanti D, Suwantika AA, Postma MJ, et al. Economic evaluation of COVID-19 vaccination: A systematic review. J global health. 2023;13:06001.","journal-title":"J global health"},{"issue":"6","key":"15121_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1377\/hlthaff.2020.00426","volume":"39","author":"SM Bartsch","year":"2020","unstructured":"Bartsch SM, Ferguson MC, McKinnell JA, O\u2019Shea KJ, Wedlock PT, Siegmund SS, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff (Millwood). 2020;39(6):927\u201335.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"15121_CR32","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1038\/s41467-021-26557-5","volume":"12","author":"KP Reddy","year":"2021","unstructured":"Reddy KP, Fitzmaurice KP, Scott JA, Harling G, Lessells RJ, Panella C, et al. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nat Commun. 2021;12(1):6238.","journal-title":"Nat Commun"},{"key":"15121_CR33","unstructured":"Centre for Respiratory Diseases and Meningitis. Proposed definition of COVID-19 wave in South Africa. Commun Dis Communiqu\u00e9 November 2021; 20(11). https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2021\/11\/Proposed-definition-of-COVID-19-wave-in-South-Africa.pdf"},{"key":"15121_CR34","unstructured":"National Department of Health. Media Release: Cabinet approves changes to COVID-19 regulations. 30. December 2021. https:\/\/sacoronavirus.co.za\/2021\/12\/30\/media-release-cabinet-approves-changes-to-covid-19-regulations\/"},{"key":"15121_CR35","unstructured":"Council for Medical Schemes. Annual Report 2021\/22. https:\/\/www.medicalschemes.co.za\/cms-annual-report-2021-22\/"},{"issue":"9","key":"15121_CR36","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593\u2013607.","journal-title":"J Infect Dis"},{"key":"15121_CR37","doi-asserted-by":"crossref","unstructured":"Wolff Sagy Y, Feldhamer I, Brammli-Greenberg S, Lavie G. Estimating the economic burden of long-Covid: the additive cost of healthcare utilisation among COVID-19 recoverees in Israel. BMJ Global Health. 2023;8(7).","DOI":"10.1136\/bmjgh-2023-012588"},{"issue":"6","key":"15121_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-024-02987-8","volume":"30","author":"M Cai","year":"2024","unstructured":"Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat Med. 2024;30(6):1564\u201373.","journal-title":"Nat Med"},{"issue":"7","key":"15121_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.vaccine.2020.12.078","volume":"39","author":"M Kohli","year":"2021","unstructured":"Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39(7):1157\u201364.","journal-title":"Vaccine"},{"issue":"1","key":"15121_CR40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1080\/13696998.2021.1965732","volume":"24","author":"WV Padula","year":"2021","unstructured":"Padula WV, Malaviya S, Reid NM, Cohen BG, Chingcuanco F, Ballreich J, et al. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021;24(1):1060\u20139.","journal-title":"J Med Econ"},{"issue":"10","key":"15121_CR41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamainternmed.2022.4299","volume":"182","author":"FP Havers","year":"2022","unstructured":"Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern Med. 2022;182(10):1071\u201381.","journal-title":"JAMA Intern Med"},{"key":"15121_CR42","unstructured":"Discovery Health. When are you fully vaccinated? September 2021. https:\/\/www.discovery.co.za\/corporate\/covid19-when-are-you-fully-vaccinated"},{"key":"15121_CR43","unstructured":"World Health Organization. Summary of ICD coding for COVID-19. South African WHO-FIC Collaborating Centre. 2021. http:\/\/www.whofic.org.za\/sites\/default\/files\/articles\/SummaryICDcoding.pdf."},{"key":"15121_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annepidem.2024.02.007","volume":"92","author":"C MacCallum-Bridges","year":"2024","unstructured":"MacCallum-Bridges C, Hirschtick JL, Patel A, Orellana RC, Elliott MR, Fleischer NL. The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020\u20132022. Ann Epidemiol. 2024;92:17\u201324.","journal-title":"Ann Epidemiol"},{"key":"15121_CR45","unstructured":"World Health Organisation. South Africa-WHO data. https:\/\/data.who.int\/countries\/710"},{"key":"15121_CR46","doi-asserted-by":"crossref","unstructured":"Edoka I, Silal S, Jamieson L, Meyer-Rath G. A cost-effectiveness analysis of South Africa\u2019s COVID-19 vaccination programme. Vaccine. 2024;42(20):125988.","DOI":"10.1016\/j.vaccine.2024.05.036"},{"issue":"4","key":"15121_CR47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40258-024-00880-6","volume":"22","author":"E Chang","year":"2024","unstructured":"Chang E, Li H, Zheng W, Zhou L, Jia Y, Gu W, et al. Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis. Appl Health Econ Health Policy. 2024;22(4):457\u201370.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"15121_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13561-023-00430-1","volume":"13","author":"R Izadi","year":"2023","unstructured":"Izadi R, Hatam N, Baberi F, Yousefzadeh S, Jafari A. Economic evaluation of strategies against coronavirus: a systematic review. Health Econ Rev. 2023;13(1):18.","journal-title":"Health Econ Rev"},{"issue":"7","key":"15121_CR49","doi-asserted-by":"publisher","first-page":"e961","DOI":"10.1016\/S2214-109X(22)00114-0","volume":"10","author":"W Jassat","year":"2022","unstructured":"Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Global Health. 2022;10(7):e961\u20139.","journal-title":"Lancet Global Health"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15121-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:02:07Z","timestamp":1792152127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15121-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15121"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15121-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9290718\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for the use of the secondary database used to conduct this study was granted by the Faculty of Health Sciences Human Research Ethics Committee of the University of Cape Town \u2013 approval number HREC Ref: 606\/2023. This study was performed in accordance with the Declaration of Helsinki. No individual consent was required as the research was based on anonymised secondary claims data. Data for the study were made available as part of NMG Consultants and Actuaries (NMG) commitment to support research initiatives with broader public health significance. The data were accessed in terms of and under the conditions set out in the agreement between NMG and the client schemes and between NMG and the researcher. The terms set out in these agreements ensured that the access to and use of the data is in full compliance with the requirements of the Protection of Personal Information (PoPI) Act in South Africa. All the data were provided in a de-identified format and aggregated at an individual level and the research team had no access to information that would enable the identification of any individual. All findings are presented at an aggregate level and no confidential member, health care provider or scheme information is disclosed. Individual consent for the data was therefore not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1420"}}